Innoviva: Underappreciated Strength In Hospital Therapeutics

Core Insights - Innoviva (NASDAQ: INVA) focuses on a robust portfolio of revenue-generating assets rather than solely on high-growth biotech and pharma stocks [1] Company Overview - Innoviva is primarily recognized for its royalty stream from GSK, indicating a stable income source [1] Investment Strategy - The company emphasizes understanding and investing in disruptive technologies and forward-thinking enterprises, suggesting a strategic approach towards innovation and future trends [1]